{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T10:27:56Z","timestamp":1793528876233,"version":"4.5.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euo.2026.08.012","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:34:23Z","timestamp":1790451263000},"page":"1192-1193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to Roberto M. Scarpa\u2019s Letter to the Editor re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non\u2013muscle-invasive Bladder Cancer: An Expert Consensus. Eur Urol Oncol 2026;9(3):652\u20139"],"prefix":"10.1016","volume":"9","author":[{"given":"Paolo","family":"Gontero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Babjuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.08.012_b0005","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.euo.2026.05.007","article-title":"Unmet treatment need and challenges associated with comparative evidence generation in BCG-unresponsive non-muscle-invasive bladder cancer: an expert consensus","volume":"9","author":"Gontero","year":"2026","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.08.012_b0010","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.08.012_b0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: Report of a Food and Drug Administration and American Urological Association public workshop","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.euo.2026.08.012_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1859461","article-title":"Sequential gemcitabine-docetaxel in BCG-na\u00efve and BCG-failure non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"16","author":"Alhubaishy","year":"2026","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2026.08.012_b0025","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/bju.16837","article-title":"Rethinking research in urology: pitfalls from the talent incubator programme","volume":"136","author":"Cerrato","year":"2025","journal-title":"BJU Int"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:33:22Z","timestamp":1793525602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126002439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2588931126002439"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.08.012","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to Roberto M. Scarpa\u2019s Letter to the Editor re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non\u2013muscle-invasive Bladder Cancer: An Expert Consensus. Eur Urol Oncol 2026;9(3):652\u20139","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}